Literature DB >> 26653871

Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.

Nicolae Balan1, Kay Osborn1, Alison J Sinclair1.   

Abstract

Repression of the cellular CIITA gene is part of the immune evasion strategy of the γherpes virus Epstein-Barr virus (EBV) during its lytic replication cycle in B-cells. In part, this is mediated through downregulation of MHC class II gene expression via the targeted repression of CIITA, the cellular master regulator of MHC class II gene expression. This repression is achieved through a reduction in CIITA promoter activity, initiated by the EBV transcription and replication factor, Zta (BZLF1, EB1, ZEBRA). Zta is the earliest gene expressed during the lytic replication cycle. Zta interacts with sequence-specific elements in promoters, enhancers and the replication origin (ZREs), and also modulates gene expression through interaction with cellular transcription factors and co-activators. Here, we explore the requirements for Zta-mediated repression of the CIITA promoter. We find that repression by Zta is specific for the CIITA promoter and can be achieved in the absence of other EBV genes. Surprisingly, we find that the dimerization region of Zta is not required to mediate repression. This contrasts with an obligate requirement of this region to correctly orientate the DNA contact regions of Zta to mediate activation of gene expression through ZREs. Additional support for the model that Zta represses the CIITA promoter without direct DNA binding comes from promoter mapping that shows that repression does not require the presence of a ZRE in the CIITA promoter.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26653871      PMCID: PMC5381392          DOI: 10.1099/jgv.0.000369

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  50 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.

Authors:  Markus Kalla; Anne Schmeinck; Martin Bergbauer; Dagmar Pich; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  A mechanism for TAFs in transcriptional activation: activation domain enhancement of TFIID-TFIIA--promoter DNA complex formation.

Authors:  P M Lieberman; A J Berk
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

Review 5.  Function and regulation of class II transactivator in the immune system.

Authors:  Cheong-Hee Chang; Tania S Gourley; Tyler J Sisk
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function.

Authors:  Thomas E Morrison; Shannon C Kenney
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

7.  The zipper region of Epstein-Barr virus bZIP transcription factor Zta is necessary but not sufficient to direct DNA binding.

Authors:  Matthew R Hicks; Salama S Al-Mehairi; Alison J Sinclair
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  CpG-methylation regulates a class of Epstein-Barr virus promoters.

Authors:  Martin Bergbauer; Markus Kalla; Anne Schmeinck; Christine Göbel; Ulrich Rothbauer; Sebastian Eck; Anna Benet-Pagès; Tim M Strom; Wolfgang Hammerschmidt
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

9.  Epigenetic control of viral life-cycle by a DNA-methylation dependent transcription factor.

Authors:  Kirsty Flower; David Thomas; James Heather; Sharada Ramasubramanyan; Susan Jones; Alison J Sinclair
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

Review 10.  Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.

Authors:  Jianmin Zuo; Martin Rowe
Journal:  Viruses       Date:  2012-08-22       Impact factor: 5.048

View more
  4 in total

Review 1.  HLA variation and disease.

Authors:  Calliope A Dendrou; Jan Petersen; Jamie Rossjohn; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2018-01-02       Impact factor: 53.106

Review 2.  Contribution of the KSHV and EBV lytic cycles to tumourigenesis.

Authors:  Oliver Manners; James C Murphy; Alex Coleman; David J Hughes; Adrian Whitehouse
Journal:  Curr Opin Virol       Date:  2018-09-28       Impact factor: 7.090

Review 3.  Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options.

Authors:  Valli De Re; Giulia Brisotto; Ombretta Repetto; Mariangela De Zorzi; Laura Caggiari; Stefania Zanussi; Lara Alessandrini; Vincenzo Canzonieri; Gianmaria Miolo; Fabio Puglisi; Claudio Belluco; Agostino Steffan; Renato Cannizzaro
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

4.  EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.

Authors:  Chenhe Su; Fang Lu; Samantha S Soldan; R Jason Lamontagne; Hsin-Yao Tang; Giorgia Napoletani; Paul J Farrell; Italo Tempera; Andrew V Kossenkov; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2021-08-05       Impact factor: 7.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.